 | While drug eluting stents have been successful in reducing the rate of restenosis following percutaneous coronary intervention, there have been safety scares over a new problem: “in-stent thrombosis”. Opinion leaders are divided over the gravity of this problem, but positive safety data are required to restore physician confidence in drug eluting stents. |
|
| The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the majority of leading CNS blockbuster brands, the market continues to offer a wealth of lucrative opportunities for all types of drug manufacturer. |
|
| In 2007, the market value of HRT for menopausal symptoms saw its first upturn since the Women’s Health initiative (WHI) study results in 2002; highly publicized findings which linked HRT to cancer and cardiovascular safety risks. The recent growth of the market is due in part to the increasing price of HRT products but can only be sustained by a similar increase in volume sales. |
|
| As the reimbursement status for the cost of hospital-acquired infections is under pressure by payors, interest in preventing these complications at the outset is growing. Nosocomial vaccines offer one route of prevention. This report assesses the clinical pipeline candidates five key nosocomial pathogens and their potential market environment including target population size estimates. |
|
| Non-small cell lung cancer accounts for about 80% of all lung cancers. In 2008, the incidence of NSCLC is forecast to exceed 367,000 new cases in the seven major pharmaceutical markets. The high incidence of the disease and the large unmet need make NSCLC an attractive market for new drug development. |
|
| Advanced heart failure is a growing issue. Existing pharmacological strategies increase the survival rates of acute heart failure patients, providing a growing source of patients with advanced disease. In view of long waiting lists for heart transplantation and the growing lack of donors, cardiac resynchronization and mechanical circulatory support devices have demonstrated promising results. |
|
| Incidence of breast cancer in the seven major markets will total 455,000 in 2008, while 115,000 women will die from the disease. Despite advances in treatment over the past decade, significant unmet needs remain. This level of demand and the large patient potential make breast cancer a relatively attractive indication for drug developers. |
|
| The ADHD market is currently valued at $3.85 billion and is set to increase over the next 10 years at a CAGR of 1.2%. Despite the continuing dominance of stimulant drugs, the 2002 launch of Strattera, the first non-stimulant treatment for ADHD, and the 2006 launch of Daytrana have served to open up the market, giving patients and physicians a greater choice of treatment options. |
|
| An overview ofthe market for portable inhalers, looking at market shares,usefulness as tools for franchise protection and -expansion. Patient- and physician preferences are being analyzed as well as suitablility of molecules and inhaler types., |
|
| The Critical Care Community is currently at its most organized, and motivated, and on a mission to improve outcomes in sepsis. This is driving a rigorous assessment of care strategies which is gathering speed and showing results. This will yield many opportunities for developing products, but current interventions' roles will change, with impacts on how they are measured, used and valued. |
|
| The opioid market is currently valued at $7.7 billion and is set to increase over the next 10 years at a CAGR of 2.4%. Despite this market being exclusively comprised of old genericized molecules, novel formulations and delivery methods have stimulated growth over the last 5 years. This growth is set to continue as current market players instigate lifecycle management strategies to retain value. |
|
| With the AD market entering a pivotal phase, Datamonitor has conducted several scenario forecasts in order to explore the possible market outlook over the next 10 years. Several pioneering Phase III disease slowing therapies offer blockbuster potential. However, should these drugs fail Phase III trials, generic competition of current therapies will see the market value decline. |
|
| Antibody-based agents represent a novel approach to the treatment and prophylaxis of infectious diseases. In recent years, considerable interest has been expressed in their further development, driven by advances in technology that improve manufacturing cost and tolerability: fully human antibody reagents avoid the toxicities associated with traditional human- or animal-derived serum therapy. |
|
| Ideally drug supply should be a simple and transparent chain that connects the manufacturer and patient in as few steps as possible, however in practice it can be a highly circuitous one that includes several intermediaries before reaching a pharmacy. This increases the risk of counterfeit drugs and facilitates parallel trade, both leading to lost sales for the manufacturer. |
|
| SLE is a chronic, life-long and potentially fatal autoimmune disease characterized by multiple system distress and unpredictable flares. Therapy is largely off-label and a huge demand exists for new SLE therapies because of the potential for serious side effects from drugs currently used in the management of the disease. |
|
| Today, pharma companies face growing competition from generics and me-too drugs, combined with increasingly tough P&R, a clamp down on healthcare spending, and the need to treat patients for longer due to the aging population. These factors threaten both current and future revenues prompting Pharma to adopt a range of corporate strategies to respond to the changing market dynamics. |
|
| Bone metastases are a complication of some advanced cancers including cancers of the breast, lung, prostate, kidney and thyroid. The incidence of bone metastases across these tumor types in the seven major markets is forecasted to total 225,174 in 2008. While treatment with bisphosphonates reduces the risk of skeletal complications, they do not improve survival in the majority of patients. |
|
| Latin American countries have attracted a lot of attention recently. With their economies currently stable, their geographic location and low-cost is ideal for investors. In addition, having such a high and varied population eases recruitment for clinical trials, and the demographics show there is a very high need for pharmaceuticals. |
|
| Datamonitor's OTC Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the OTC pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis. |
|
| Datamonitor's Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis. |
|
| Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy and is comprised of around 30 different disease subtypes. Each of these present with a distinct set histological, genetic and clinical characteristics. Treatment options in NHL include chemotherapy, targeted therapies, stem cell transplantation and radiotherapy. |
|
| Prostate cancer is one of the four most common tumor types, and is the most common cancer and second most common cause of cancer-related death to affect men. Prostate cancer is curable when localized and frequently responds to treatment at an advanced stage. The rate at which prostate tumors grow varies between patients, with some achieving prolonged survival even with metastatic disease. |
|
| In May 2006 Bausch & Lomb's ReNu with MoistureLoc contact lens solution was permanently withdrawn from markets worldwide due to an outbreak of a fungal eye infection. For a large market player, the loss of a new revenue driver and the negative publicity surrounding the event is likely to have a significant impact on future success, as well as implications for other companies in the sector. |
|
| Existing sales and marketing models are considered unsustainable. Pharma has been slow to adapt and take advantage of the marketing opportunities offered by the internet. Meanwhile customers are increasingly using the web to source information. Pharma needs to evolve and engage with their customers online, or risk being left behind. |
|
| With dwindling growth rates observed in the major developed markets many pharmaceutical companies are turning towards emerging market countries in order to sustain their revenue growth. While some countries, with double digit growth rates present tremendous opportunities, there are also many obstacles that need to be overcome. |
|
| A total of 11 companies make up the top five across each of the four ID sectors, their core competencies ranging from a single disease area to generics prowess, producing a comprehensive portfolio to providing a specific offerings corresponding to highest unmet need. This report characterises the key players in each sector, and their approach to maximising their returns from a pressurised sector. |
|
| The face of ACS is changing. The ageing population and pressure of growing risk factors have made a significant impact on the management strategies in ACS. This report unveils the true picture through in-depth analysis of data on over 21,000 ACS patient records in the 5 major European pharmaceutical markets (5EU; France, Germany, Italy, Spain and the UK). |
|
| Type 2 diabetes is an emerging epidemic driven by the escalating prevalence of obesity and by an ageing population. Diagnosis rates will continue to increase as improved awareness raises the public profile of the disease. Despite several established classes of oral anti-diabetic agents an unmet need for a safe, efficacious agent which can halt or reverse long-term disease progression remains. |
|
| The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key brands expected to be Pfizer's Detrol LA (tolterodine) and Toviaz (fesoterodine), GSK's Vesicare (solifenacin), and Novartis' Enablex (darifenacin). |
|
| The autoimmune disease market will be rapidly growing due to a high number of competitive brands currently on the market and a full pipeline. Company strategies include expanding the treatment algorithm by pursuing approval for 'early' disease stages, launching easy-to-use devices to make up for downsides of injectable drugs, and developing fully human monoclonal antibodies as follow-on products. |
|
| The generics market is growing, driven by rising healthcare costs and fed by a steady stream of patent expiries. Levels of generic uptake vary widely across the 7 major markets, with important implications for industry strategy. |
|
| Counterfeit medicines are a global problem costing patient's their health and the pharmaceutical industry and governmental organizations millions of dollars per year. Although there is no one preventative strategy, there are several measures that can be employed simultaneously to reduce the risk of fake medicines entering the pharmaceutical supply chain. |
|
| Research and Development activity in the Hepatitis C arena continue to be high. The market still holds many areas of unmet medical needs: while existing therapies provide good efficacy for about half of the patient population, side effects and limited efficacy in other patients offer much room for improvement. Several development setbacks over the past 18 months highlight the obstacles in R&D. |
|
| Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. With a forecast incidence of 36,769 across the seven major markets in 2007, they are one of the most common hematological malignancies. Currently, the only potentially curative option is hematopoietic stem cell transplantation but this is only suitable for a small subset of patients. |
|
| Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy and is comprised of around 30 different disease subtypes. Each of these present with a distinct set histological, genetic and clinical characteristics. Treatment options in NHL include chemotherapy, targeted therapies, stem cell transplantation and radiotherapy. |
|
| The incidence of multiple myeloma is forecast to total 40,885 cases across the seven major pharmaceutical markets in 2007. Current drug therapy is planned around stem cell transplantation. The recent approval of three new agentsThalomid (thalidomide; Celgene), Revlimid (lenalidomide; Celgene) and Velcade (bortezomib; Millenium/Johnson & Johnson)has significantly advanced treatment. |
|
| Endometriosis is a painful, menstrual-related disorder that is thought to affect approximately 10% of the female population of reproductive age. Despite this large patient potential, growth of the endometriosis market has been limited by low levels of investment, poor awareness among physicians and the public, problematic diagnosis, and lack of effective therapies. |
|
| Based on an analysis of 43 companies and 1,200+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 3.2% CAGR 2006 to 2012. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening. |
|
| Peripheral artery disease, sometimes also referred to as peripheral vascular disease, is atherosclerosis in peripheral regions, which can lead to loss of blood flow to the limbs, and can result in loss of life, limb amputation and cardiovascular events. The current pharmacological treatment options are limited, and there are large unmet needs associated with the disease. |
|
| The continued uptake of existing brands and the launch of two opioid antagonists will cause the market to grow at a compound annual growth rate of 13.5% from 2006 to reach $304m across the seven major markets by 2016. The alcohol dependence market requires a paradigm shift away from the public perception that it is a behavioral disorder towards being regarded as a treatable medical condition. |
|
| The ALS market was worth $148m in 2006 across the seven major markets. With the only approved treatment for ALS, Sanofi-Aventis's Rilutek (riluzole), facing generic incursion in 201213, future growth in this market is dependent on the success of pipeline drugs. |
|
| Treatment of HIV has come a long way since the discovery of the virus. Although no real cure has been found yet, the last few decades have seen the introduction of many classes of drugs that suppress the replication of the virus. As therapeutics have improved dramatically in terms of efficacy, safety and convenience, the bar for new drugs has been raised considerably. |
|
| Parkinson's disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the seven major markets (7MM); with patients typically being diagnosed in their early sixties and living for over 18 years after the onset of first symptoms. |
|
| Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhea and abdominal pain. IBD includes key subsets Crohn's disease and ulcerative colitis, both of which can significantly impact on the quality of life of an individual. |
|
| As a result of market dominance by agents such as leuprolide, and AstraZeneca’s Zoladex (goserelin) and Casodex (bicalutamide), there is little space in the antihormonal therapies market for new competition unless significant clinical superiority or a unique selling point is demonstrated. While Taxotere-based chemotherapy is the established first-line standard for hormone-refractory prostate cancer, many patients are still precluded from treatment due to toxicity concerns. This, coupled with a lack of second-line standard therapy, indicates a major gap in the market that could be potentially lucrative for drug developers. Enthusiasm has been shown by key opinion leaders regarding certain late-phase pipeline products, however, during the time of writing, publication of negative clinical trial data has meant a dampening of this optimism. It will therefore be some time before the high unmet needs in the hormone-refractory prostate cancer market are satisfied. |
|
| Despite being one of the most common hereditary diseases among Caucasians, low physician awareness and a lack of disease-modifying drugs have led to massive underdiagnosis of the condition. the resulting perceived small number of patients and restricted market is a major obstacle for the development of new treatments.Understand the epidemiology of alpha-1 antitrypsin deficiency and assess the untapped patient potential. Evaluate current strategies for the diagnosis and treatment of this disease. Assess the potential for new drugs and their potential for additional uses Gain an understanding of some of the principal challenges in the treatment of alpha 1 antitrypsin deficiency as defined by key opinion leaders. |
|
| Key issues in head and neck cancer including disease overview and epidemiology, current treatment patterns and controversies, unmet needs and key stakeholder opinions. The clinical pipeline and profiles of the late-phase products are also included. |
|
| The systemic antifungals market accounts for $3.1bn of the total $41bn anti-infectives market. A wave of new products coinciding with patent expiry of two widely used compounds will shake up the market for systemic infections, further polarizing between winners and losers. Key changes are forcing a rethink of management strategies and clinical trial design. |
|
| The current Huntington’s disease market is comprised of off-label prescriptions of psychotropic drugs. In the near term, two pipeline drugs are set to enter the market, demonstrating the viability of this disease as a primary marketing indication. In the longer term, with a strong genetic link and reliable diagnostic test, prophylactic treatment with a disease modifying drug could prove lucrative. |
|
| With Pharma struggling to maintain its pipelines and portfolios with products developed in-house, companies are increasingly turning to licensing. However, the search for late-stage developmental products is becoming tougher and more expensive, and companies are now looking towards licensing earlier-stage compounds. |
|
| The high prevalence of nicotine dependence, strong uptake of Pfizer’s Chantix (varenicline), and the launch of new innovative therapies will cause the nicotine dependence prescription drug market to grow to $4.6 billion across the seven major markets by 2016. Innovative therapies are set to offer patients a convenient dosing regimen and thereby carrying the potential for improved compliance. |
|
| Fuelled by an increasing disease awareness, the growing use of new, expensive drugs as well as combination therapy, the HBV drugs market, sized at $431m in 2006 across the seven major markets, will nearly triple in size by 2016. Rapid growth until 2011 will slow down in the following years as a result of genericization and the beginning impact of routine HBV vaccination. |
|
| Datamonitor expects the cardiovascular market to remain stable with sales only showing negligible growth between 2006 and 2016, below the 3% growth predicted for the SU sold. Generic products will become increasingly important as the majority of products will have lost IP protection, accounting for 30% of cardiovascular sales and 65% of SU sold in 2016. |
|
| Approaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge. |
|
| Drug targets are the critical link between drugs and their role in the treatment of medical disorders. By grouping drug targets into key protein families, this report provides a comprehensive analysis of the prescription pharmaceutical market by not just molecule type and therapy area, but also by target family. |
|
| Stroke is one of the top three leading causes of death worldwide and an area of high unmet needs. TPA is limited to a low number of ischemic stroke patients due to a short therapeutic time window, but it is still the best therapy available. TPA is responsible for major changes and advances in the way stroke patients are cared for, which is expected to evolve further. |
|
| In the 7 major markets, Datamonitor estimates that the incidence of RCC in 2007 will total 86,800 cases. Around 25% of all RCC patients are diagnosed with Stage IV disease; the 2-year survival rate for these patients is around 23%. This low survival rate and the fact that a significant proportion of Stage IIII patients relapse with Stage IV disease mean there is significant unmet need in RCC. |
|
| Datamonitor expects the antithrombotics market to peak at just over $20 billion in 2012, across the seven major markets. The growth will be driven by the uptake of the novel oral anticoagulants - Bayer's Xarelto and BI's Rendix - which are expected to launch simultaneously, in 2008. |
|
| The market for infertility drugs is a complex and dynamic arena shaped by numerous factors such as changing social attitudes, national legislation, and prescriber preferences. Brand strength and diverse portfolios have allowed Organon, Merck Serono and Ferring to secure a firm foothold in the market, worth over $1 billion in 2006, and represent tough competition. |
|
| The allergic rhinitis market will continue to decline over the next few years, after which it will resume limited growth due to the introduction of new compounds and combination products. These will drive the expansion of sales in existing classes as they exhibit safety and convenience advantages. Meanwhile, immunotherapy is expected to move from its niche position into mainstream therapy. |
|
| The upper GI market, defined as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD) and dyspepsia indications, achieved sales of just over $19 billion in 2006, with minimal growth since 2005. All major PPI brands will lose patent protection in the next 10 years, resulting in a major increase in generics and a declining market value. |
|
| Despite several developments in efforts to tackle the spread of HIV, the total number of people living with HIV has continued to increase across the 6MM. However, significant advances in HIV disease understanding, treatment and management mean that the outlook for patients has considerably improved. |
|
| Datamonitor's Orthopedics: Global Industry Guide is an essential resource for top-level data and analysis covering the orthopedics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis. |
|
| Datamonitor's Biotechnology: Global Industry Guide is an essential resource for top-level data and analysis covering the biotechnology industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis |
|
| Datamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis. |
|
| Significant barriers to entry into the biosimilars market exist. High up-front investment and the need for specific expertise favor big players. Understanding of the marketplace is critical for success acceptance by key stakeholders is crucial for market uptake of biosimilars and achieving preferential reimbursement status through constant review of the pricing strategy is desirable. |
|
| In 2007, more than 3 million new cases of solid tumors are forecast to be diagnosed across the seven major pharmaceutical markets, obviously representing an enormous market potential. Lower incidence tumor types are becoming increasingly attractive to drug developers, due to high levels of unmet need which can result in significant financial rewards. |
|
| The PD market is set to continue to grow over the next 7 years, reaching over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expected to be Novartis/Orion's Stalevo, GlaxoSmithKline's (GSK's) Requip Modutab, and UCB-Schwarz's Neupro. |
|
| NICE is one of the most advanced cost effectiveness assessment bodies operating in the major pharmaceutical markets. Since it was established it has had an increasing impact on the availability of new drugs in England and Wales, but has also generated considerable attention globally |
|
| The neuropathic pain market is forecast to double from 2006 to reach over $7 billion by 2016. At this time, the current late-stage neuropathic pain pipeline is forecast to take only 18% of the total market share, highlighting an opportunity for better pipeline drugs that demonstrate improved pain management. The most promising and closest pipeline drug to market is UCB's Vimpat (lacosamide). |
|
| With the seven triptan brands continuing to dominate acute migraine treatment and Ortho-McNeil's Topamax (topiramate) driving sales in the prophylactic market, 7MM revenues of anti-migraine drugs increased by 8.1% from 2005 to $3.7 billion in 2006. The US accounted for 80% of the 7MM total in 2006, Whilst in the 5EU, France is the largest market for migraine-specific drug sales. |
|
| "IntroductionThis report provides a comprehensive strategic analysis of the mAb market out to 2012 by company. It identifies four 'established' and four 'emerging' players within the mAb sector which are forecast to play the most commercially significant role within this market. |
|
| The long-standing unmet need of the osteoporosis market has been for improved adherence to treatment. Two pipeline products, Amgen's Denosumab and Novartis' Aclasta (zoledronate), have answered this demand with intermittent dosing schedules and consequently are expected to generate blockbuster revenues. This will rejuvenate the market which is otherwise stalling under multiple patent expiries. |
|
| Europe serves as a model for other countries looking to define their own regulatory approval criteria. The US is on the brink of passing legislation to establish a statutory pathway for biosimilars approval but the opposing interests of biosimilar and innovative companies may result in further delays. Development of biosimilars presents many challenges and potential pitfalls. |
|
| The Hospital antibacterials market accounted for $9.9bn of the total $41bn anti-infectives market. Increasingly resistant and problematic pathogens make this an attractive target for premium priced products outside of the largely genericized Community market. However, high concentrations of patent expiries and similarly targeted product launches imply a highly competitive commercial landscape. |
|
| Social media are shifting the way that the global economy operates. Internet journals and communities have enabled consumers to communicate their experiences with companies' products and services to other consumers. A consequence of consumer-generated marketing is that relationship management throughout the lifecycle of a product is taking the place of mass marketing in consumer-driven industries. |
|
| The diabetes epidemic has contributed in the growth of the antidiabetics market the past few years. Since the prevalence of diabetes continues to increase, the market will further expand. While early therapy is dominated by generically available agents, and the later stages by insulin, the number of unmet needs in the diabetes treatment, warrants that novel agents will have a place in the market. |
|
| With fewer truly novel products entering the market, combined with increasing developmental time and spend, and declining ROI, successful launches have never been more important for pharmaceutical companies. Therefore, to ensure a successful launch, manufacturers must employ a multitude of timely strategies to ensure their product enter the market as soon and as smoothly as possible. |
|
| Datamonitor expects few new products to emerge from a week pipeline for both acute and chronic heart failure. Sales in the seven major markets will be modest with all the new drugs being add-on therapies to current standard regimes. Significant unmet patients needs will remain in both acute and chronic heart failure. |
|
| Waves of technological advancements have powered significant evolution in R&D from serendipitous drug discovery, through to rational drug design. However, as the low-hanging fruit has been picked, and recent technological advances have failed to yield high numbers of new therapies, the search is on to identify R&D strategies to improve R&D productivity |
|
| Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently there is just one product approved for the treatment of FSD; P&G's Intrinsa (testosterone) is marketed in Germany, France and the UK. |
|
| The pediatric and adolescent vaccines market encompasses many different classes. DTP and MMR combinations continue to form the mainstay of childhood immunization; however, their growth potential is limited. The key opportunities lie in novel, innovative additions to established schedules, particularly pneumococcal (Prevnar), conjugated meningococcal (Menactra) and HPV (Gardasil) vaccines. |
|
| Datamonitor has identified the key trends and events that drive patient empowerment and impact the pharmaceutical industry. These range from the increased access to information via internet and the rising pressures of cost containment through to how patient empowerment is affecting access to drugs as well as changing pharmaceutical marketing strategies and their public image. |
|
| Datamonitor expects the antihypertensives market to reach almost $40 billion, across the seven major markets, by 2016. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and Merck's Cozaar, will restrain market growth. |
|
| The restrictive, highly competitive antidyslipidemic market is going to become even further genericized, which will add to the challenges that drug makers are facing. Despite over 300m people being eligible for antidyslipidemic treatment, there is still a lot of under-diagnosis and under-treatment, but it will be a major issue capturing all the eligible population. |
|
| Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major markets. |
|
| Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds, factoring in clinical trial results, new product launches and patent expiries.Scope of this report * In-depth analysis of the current HIV market across the major US and EU markets * Thorough assessment of underlying commercial and clinical factors shaping the antiretroviral market * Detailed sales forecasts for the three major antiretroviral classes, molecules and brands in each of the six major markets * Case study analysis of the entry inhibitor class focusing on the competitive environment and critical success factors |
|
| Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and peptic ulcer disease (PUD) represent a group of common gastrointestinal (GI) conditions, which can be referred to collectively as upper GI disorders. Gastric acid suppression remains the cornerstone of therapy in upper GI disorders, with particular focus on reducing symptoms and eradicating H. pylori, if present. |
|
| Sales of the Top 20 cancer therapy brands in each of the seven major markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6.6% to $45.9 billion by 2016. Four newly marketed drugs are expected to become part of the Top 20 cancer therapy brands during the forecast period and are set to increase the 2016 sales of the existing Top 20 cancer therapy brands to $52.7 billion. |
|
| Failure to take medication as prescribed significantly increases the risk that patients will experience complications resulting in injury or death, and propagate higher healthcare costs overall. The medical establishment's approach to adherence is changing as it becomes clear that the responsibility of achieving adherence is not solely the patient's, but rather is shared among stakeholders. |
|
| Incidence of primary brain cancer across the seven major markets in 2007 is estimated to be 47,000. Over half of these cases will be glioblastoma multiforme, for which survival prospects are dismal. The median survival for this group of patients is 1.2 years and only 27% of patients are alive after two years. The level of unmet need is therefore high in this disease. |
|
| Novel pipeline drugs, lifecycle management of the current branded antidepressants, and development of atypical antipsychotics for depression are set to grow the depression market through to 2010 when it will peak at $14.6 billion. Thereafter, however, generic incursion of the atypical antipsychotics and the remaining branded antidepressants will see the depression market value drop to 2016. |
|
| Ambien has remained the clear leader in the insomnia market for over a decade, with 2006 sales of over $2.3 billion across the seven major markets. The success of Ambien is attributable to a favorable side-effect profile and half-life. However, due to recent patent expiries in the US and Japan, Ambien's leadership status is finally under threat and the market is undergoing some dramatic changes. |
|
| The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of a new MS treatment for six years. |
|
| The osteoporosis market is due a major upheaval when market leader Fosamax (alendronate) loses its US patent. The resultant heightened competition will force market players to implement radical lifecycle management strategies to safeguard their franchise revenue. New market entrants provide further complexity to the competitive landscape but will also drive market growth over the next ten years. |
|
| The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics. |
|
| The telehealth market will continue to grow as the population, particularly the elderly and chronically ill, and technology adoption increase. |
|
| The telehealth market will continue to grow as the population, particularly the elderly and chronically ill, and technology adoption increase. |
|
| Irritable bowel syndrome (IBS) is a common disease affecting 1020% of the total adult population, particularly women, in which recurrent abdominal pain or discomfort is associated with defecation or changes in bowel habit. The majority of sufferers have never consulted a physician about their symptoms and remain undiagnosed. |
|
| Supportive care can be defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies, in particular cytotoxic chemotherapy. While the antihormonal therapies and novel molecular targeted therapies do not exist without some toxicity, these are not as severe as those associated with chemotherapy. |
|
| The close association with hepatitis means that hepatocellular carcinoma (HCC) is common in developing countries where hepatitis B and C infections are endemic. However, the increasing prevalence of hepatitis in the West means that incidence of HCC in the US and Europe is expected to increase significantly over the coming years. |
|
| The Canadian pharmaceutical market is the 8th largest globally and as such represents an important market for generics manufacturers. Although historically dominated by domestic generics companies, mergers and acquisitions over the last five years have increased the dominance of foreign players. |
|
| Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the classification guidelines, further limiting diagnosis, already hampered by embarrassment, lack of physician awareness and an unclear referral system. |
|
| Mainly affecting women, fibromyalgia syndrome affects six million people in the US alone. This relatively common yet poorly understood syndrome is characterized by widespread muscle pain and fatigue and remains substantially underserved by the medical profession and the pharmaceutical industry. Currently, there are no drugs licensed to treat fibromyalgia in the US, Japan or Europe. |
|
| The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the last decade. The success of the next wave of novel RA therapies depends on their ability to address the key issue of cost effectiveness, as the patient population for anti-TNF's is reaching a maximum and competition moves to anti-TNF failure patients. |
|
| The launch of serotonin antagonists which are largely aimed at treating sleep maintenance is set to make a substantial impact on the insomnia market, which will increase in value across the seven major markets from $6.1 billion in 2006 to $7.7 billion in 2016. |
|
| With declining returns from drug development pipelines, preservation of branded revenues is key for manufacturers. Inevitably though, once the core product patent of a pharmaceutical drug expires, generic companies will launch their own, cheaper versions of the drug, encouraging product switching and eroding the revenues of branded pharmaceuticals. |
|
| Novel oral anticoagulants and antiplatelet agents will have a profound impact on the antithrombotics market. Datamonitor expects Bayer's rivaroxaban and Sankyo/Eli Lilly's prasugrel to achieve blockbuster status. Parenteral anticoagulants are not expected to be large revenue generators, due to low clinical unmet need in this market segment and strong competition from current gold standard agents. |
|
| At present, despite the availability of numerous agents for the treatment of dyslipidemia, there is significant scope for expanding the market by improving diagnosis and treatment of dyslipidemia patients. However, for new agents, gaining a secure foothold on the market will be challenging, but their chances can be improved through targeting niche patient populations and conducting outcome trials. |
|
| The influenza vaccine market, sized at approximately $2.2 billion in 2006, yields many challenges. Demand is highly variable, and only large players are able to cope with the need for annual updates and the costly manufacturing process. However, driven by the increasing pandemic threat, the market is growing fast and is predicted to more than double in size by 2016. |
|
| Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. Pipeline candidates classified as molecular targeted therapies, cytotoxic therapies and immunotherapeutic agents, may offer attractive therapeutic additions and Datamonitor's insight into their clinical and commercial potential is provided. |
|
| The launch of five novel orally administered disease-modifiers is set to revolutionize the multiple sclerosis (MS) market, which will more than double in value across the seven major markets from 2006 to reach $10.7 billion in 2016. |
|
|
